Company news

Share this article:

Novo Nordisk signed an exclusive agreement with Sciele Pharma to market Prandin (repaglinide). Under the terms of the agreement, Sciele will exclusively market Prandin and, upon approval by the FDA PrandiMet (the name submitted to FDA for a repaglinide/metformin fixed dose combination tablet) to physicians in the U.S., and will have a right of first refusal to obtain marketing rights in the US to other Novo Nordisk products containing repaglinide, the active pharmaceutical ingredient in both Prandin and PrandiMet. Financial terms of the deal were not disclosed.

Sepracor announced on Nov. 27 that it received notice from the Securities and Exchange Commission that an investigation concerning the company's historical stock option granting practices has been completed and that no enforcement action was recommended.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.